Tamro Sales Up 20% For Jan-Oct Period

18 November 1996

Finland's Tamro Group sales reached 10.43 billion markka ($2.3 billion) for the 10-month period January-October, 1996, an increase of 20% on the like, year-earlier figure. The strengthening Swedish krona had an effect of around nine percentage points on the growth.

Total sales of the pharmaceutical distribution division grew 21% to 9.71 billion markka, and the market share of sales of pharmaceuticals was 62% (compared with 61% in the like, 1995 period) in Finland for the 10 months and 62% (63%) in Sweden (for January through September). Sales of the hospital and laboratory division for the 10 months were 442 million markka, a rise of 19%. Company acquisitions contributed around nine percentage points to the sales increase.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight